Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-MAP2K2 Antibody (R3K04)

Catalog #:   RHE17802 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG1
Applications: FCM, IF, WB
Accession: P36507
Overview

Catalog No.

RHE17802

Species reactivity

Human, Mouse, Rat

Host species

Mouse

Isotype

IgG1

Clonality

Monoclonal

Tested applications

FCM: 1:200-1:400, IF: 1:200-1:1000, WB: 1:500-1:2000

Target

MAP kinase kinase 2, MAPK/ERK kinase 2, ERK activator kinase 2, MAPKK 2, PRKMK2, MAP2K2, MEK 2, MEK2, MKK2, Dual specificity mitogen-activated protein kinase kinase 2

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P36507

Applications

FCM, IF, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3K04

Data Image
  • Flow Cytometry
    Flow cytometric analysis of Hela cells using anti-MAP2K2 mAb (green) and negative control (purple).
  • Immunofluorescence
    Immunofluorescence analysis of Hela cells using anti-MAP2K2 mAb (green). Red: Actin filaments have been labeled with DY-554 phalloidin. Blue: DRAQ5 fluorescent DNA dye.
  • Western blot
    Western blot analysis using MAP2K2 mouse mAb against PC-12 (1), Jurkat (2), Hela (3) and NIH/3T3 (4) cell lysate.
References

Expression profile of mRNAs and miRNAs related to mitogen-activated kinases in HaCaT cell culture treated with lipopolysaccharide a and adalimumab., PMID:38557266

Case report: The cardio-facio-cutaneous syndrome due to a novel germline mutation in MAP2K1: A multifaceted disease with immunodeficiency and short stature., PMID:36313893

The MAP2K2 Gene as Potential Diagnostic Marker in Monitoring Adalimumab Therapy of Psoriatic Arthritis., PMID:35762548

Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma., PMID:31082388

Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltration in triple-negative breast cancer., PMID:30777101

Alterations of MEK1/2-ERK1/2, IFNγ and Smad2/3 associated Signalling pathways during cryopreservation of ASCs affect their differentiation towards VSMC-like cells., PMID:30273905

Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand., PMID:30250119

MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment., PMID:29767411

Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer., PMID:27636997

Inhibition of the Binding between RGS2 and β-Tubulin Interferes with Spindle Formation and Chromosome Segregation during Mouse Oocyte Maturation In Vitro., PMID:27463806

MEK1/2 inhibitors induce interleukin-5 expression in mouse macrophages and lymphocytes., PMID:27045084

ERK reinforces actin polymerization to power persistent edge protrusion during motility., PMID:25990957

Brominated flame retardants, tetrabromobisphenol A and hexabromocyclododecane, activate mitogen-activated protein kinases (MAPKs) in human natural killer cells., PMID:25341744

Selective regulation of axonal growth from developing hippocampal neurons by tumor necrosis factor superfamily member APRIL., PMID:24444792

Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines., PMID:24192080

Mitogen-activated protein kinase pathway in osteosarcoma., PMID:22935974

MEK2 regulates ribonucleotide reductase activity through functional interaction with ribonucleotide reductase small subunit p53R2., PMID:22895183

Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin., PMID:22242821

Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells., PMID:22086413

Mitogen-activated protein kinase extracellular signal-regulated kinase 2 phosphorylates and promotes Pin1 protein-dependent promyelocytic leukemia protein turnover., PMID:22033920

Acidic fibroblast growth factor (FGF) potentiates glial-mediated neurotoxicity by activating FGFR2 IIIb protein., PMID:21990352

Cerebrospinal fluid stimulates leptomeningeal and meningioma cell proliferation and activation of STAT3., PMID:21971737

Liver fibrosis protects mice from acute hepatocellular injury., PMID:21945831

Novel agents in the management of pancreatic adenocarcinoma: phase I studies. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011., PMID:21386633

Involvement of P2X(7) purinergic receptor and MEK1/2 in interleukin-8 up-regulation by LL-37 in human gingival fibroblasts., PMID:21338358

MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy., PMID:21118963

Insulin growth factor promotes human corneal fibroblast network formation in vitro., PMID:20631235

SSeCKS/Gravin/AKAP12 inhibits cancer cell invasiveness and chemotaxis by suppressing a protein kinase C- Raf/MEK/ERK pathway., PMID:20018890

Green tea (-)-epigallocatechin gallate inhibits insulin stimulation of 3T3-L1 preadipocyte mitogenesis via the 67-kDa laminin receptor pathway., PMID:19176763

Endosomal targeting of MEK2 requires RAF, MEK kinase activity and clathrin-dependent endocytosis., PMID:18657070

Atrial natriuretic peptide and long acting natriuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells., PMID:18225537

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells., PMID:17928528

Oncostatin M-induced effects on EMT in human proximal tubular cells: differential role of ERK signaling., PMID:17881458

Regulation of intracellular MEK1/2 translocation in mouse oocytes: cytoplasmic dynein/dynactin-mediated poleward transport and cyclin B degradation-dependent release from spindle poles., PMID:17507801

Subversion of B lymphocyte tolerance by hydralazine, a potential mechanism for drug-induced lupus., PMID:17404230

CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment., PMID:17307798

Global functional analysis of nucleophosmin in Taxol response, cancer, chromatin regulation, and ribosomal DNA transcription., PMID:17069796

Positive regulation of Raf1-MEK1/2-ERK1/2 signaling by protein serine/threonine phosphatase 2A holoenzymes., PMID:16239230

ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection., PMID:16051824

Platelet-derived growth factor-BB-induced human smooth muscle cell proliferation depends on basic FGF release and FGFR-1 activation., PMID:15625285

Arrangement of expression and distribution of tight junction protein claudin-1 in cell dissociation of pancreatic cancer cells., PMID:15547692

Relationship between activation of epidermal growth factor receptor and cell dissociation in pancreatic cancer., PMID:15492819

Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines., PMID:15449038

High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy., PMID:15327405

Glycogen synthase kinase-3beta is tyrosine-phosphorylated by MEK1 in human skin fibroblasts., PMID:15020233

Phosphatidylinositol 3-kinase-dependent mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 and NF-kappa B signaling pathways are required for B cell antigen receptor-mediated cyclin D2 induction in mature B cells., PMID:14978074

Use of inhibitors in the study of MAPK signaling., PMID:14755084

Phosphorylation regulates nucleophosmin targeting to the centrosome during mitosis as detected by cross-reactive phosphorylation-specific MKK1/MKK2 antibodies., PMID:14670079

Glycoprotein IIb/IIIa inhibition attenuates platelet-activating factor-induced platelet activation by reducing protein kinase C activity., PMID:12911597

Inhibition of interleukin-4-induced class switch recombination by a human immunoglobulin Fc gamma-Fc epsilon chimeric protein., PMID:12801927

Datasheet

Document Download

Anti-MAP2K2 Antibody (R3K04).pdf

 

$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-MAP2K2 Antibody (R3K04) [RHE17802]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only